Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Date:11/11/2009

NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The clinical data to be presented demonstrates the potential safety and efficacy of KRX-0401 in the treatment of patients with relapsed/refractory multiple myeloma.

    Details on the Abstract selected for poster presentation are as follows:

    Abstract #:         1869

    TITLE:  Perifosine in Combination with Bortezomib and Dexamethasone
    Extends Progression-Free Survival and Overall Survival in
    Relapsed/Refractory Multiple Myeloma Patients Previously Treated with
    Bortezomib: Updated Phase I/II Trial Results

    Lead Author:        Paul Richardson, MD

    Session Name:       Myeloma - Therapy, excluding Transplantation Poster I

    Date:               Saturday, December 5, 2009

    Presentation Time:  5:30 PM - 7:30 PM

    Location:           Ernest N. Morial Convention Center, Hall E

    Poster Board no.:   I-891

This abstract became available for viewing yesterday on the American Society of Hematology website (www.hematology.org). At the time of the abstract submission in mid-August 2009, there were 84 patients enrolled on study, of which 73 were evaluable for efficacy and are reported on within the abstract. Updated efficacy (response rate, time-to-progression and survival) and safety analyses, as of mid-November 2009, will be presented at the conference.

A copy of the above referenced abstract can be viewed online through the ASH website,

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
4. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
5. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today updates the timeline for the GMP certification ... The Company is scheduled to submit the ... & Drug Administration,s (CFDA) review in the week ...
(Date:8/28/2014)...  Decision Resources Group finds that the market for colorectal ... by 2023 in the United States , ... Italy , Spain , ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and ... the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s ...
(Date:8/28/2014)... Levi & Korsinsky announces that a class ... District Court for the District of Nevada ... Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... Period the Company violated federal securities laws by issuing ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2
... China, Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese Medicines ("TCM") in China, today announced that ... the 66th PHARMCHINA fair ("the Fair") recently held ...
... Reportlinker.com announces that a new ... its catalogue: Europe ... 2017- Glucose Monitoring and Insulin Delivery ... Europe Diabetes Care Devices ...
Cached Medicine Technology:China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 10Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 11Europe Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 12
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... 29, 2014 Until now, databases have ... or unstructured data (document stores). SQL products have handled ... basically managed the wide assortment of unstructured data. It ... with Big Data is with a NoSQL Database. Unique ... aspects of all Big Data issues. Scientel ...
(Date:8/28/2014)... Career Step, an online provider of career-focused education ... to help students and career seekers explore the opportunities ... video details what medical coders and billers do, what ... education requirements for entering this field. , “Medical coding ... people are considering a career in healthcare,” said Jerolyn ...
(Date:8/28/2014)... When David Gergen, President of Pro Player ... was asked to publicly support Mr. Brnovich in his ... seat in the State of Arizona, Mr. Gergen could ... Hall of Fame wide receiver Roy Green in addition ... Green, Kennard and Walczak are members of Pro Player ...
(Date:8/28/2014)... emergency department with complaints of nausea, vomiting, anxiety ... business lunches, and at home every evening. Worried ... and had his last Scotch 24 hours before ... in emergency rooms across Canadaa patient suddenly stops ... Withdrawal is a potentially fatal condition that is ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... ... you up-to-date on embargoed studies and other news being presented at the ... 23-27 in Seattle. All briefs are embargoed until the date/time they are ... registration, or to arrange interviews with presenters, please contact ASPS Public Relations ...
... /PRNewswire-Asia-FirstCall / -- Winner Medical,Group Inc. (OTC Bulletin Board: WWIN; ... largest exporter by volume in the medical,dressing industry in China, ... 6, 2009. , The Company will ... under the new symbol "WWIN" when market opened on October ...
... 6 People with primary immunodeficiency diseases (PIDD) and ... one another and share their experiences through a new ... Foundation (IDF) announced today. Primary immunodeficiency ... by hereditary or genetic defects in the immune system. ...
... identifies competitive advantage for employers from effective health, ... Oct. 6 To help employers gauge benefits-program ... today the country,s largest single-source benchmarking database across ... The 2008 IBI Benchmarking database compares how employers, ...
... Institutes of Health announced today a second phase of ... for 19 research consortia. The Rare Diseases Clinical Research ... be awarded a total of just over $117 million ... the new funding will explore the natural history, epidemiology, ...
... led some organizations and communities to establish smoking bans ... effectiveness of such bans in protecting people from health ... a matter of continuing debate. Secondhand-Smoke Exposure and ... report from the Institute of Medicine, provides a comprehensive ...
Cached Medicine News:Health News:Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24 2Health News:Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24 3Health News:Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24 4Health News:Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24 5Health News:Winner Medical One for Two Reverse Stock Split Becomes Effective and Begins Trading Under New Symbol: WWIN 2Health News:Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 2Health News:Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 3Health News:Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 2Health News:Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 3Health News:NIH announces expansion of Rare Diseases Clinical Research Network 2Health News:NIH announces expansion of Rare Diseases Clinical Research Network 3Health News:NIH announces expansion of Rare Diseases Clinical Research Network 4Health News:NIH announces expansion of Rare Diseases Clinical Research Network 5Health News:NIH announces expansion of Rare Diseases Clinical Research Network 6Health News:NIH announces expansion of Rare Diseases Clinical Research Network 7Health News:NIH announces expansion of Rare Diseases Clinical Research Network 8
... Your patient will be more comfortable, ... tracheostomy tube stabilization more secure and to ... tying and untying of twill ties, consider ... adult and neonate/infant sizes, the narrow fastener ...
... for ease of use and patient comfort, ... edges for comfort and is available in ... a perfect fit. For hard to fit ... collar to your specifications. Don't just take ...
... in place. Soft strap features an adjustable ... compliant foam laminate with elastic adjustment increases ... while still providing a snug fit. Soft ... prevent sliding and patient irritation, and also ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: